Smoking Abstinence and Response to Smoking Cues

This study is currently recruiting participants.

Verified by National Institute on Drug Abuse (NIDA), October 2008

Sponsored by:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00385060

Purpose

Tobacco smokers who are willing to stop smoking for up to 35 days will be randomly assigned to abstain from all nicotine use for 7 to 35 days. Participants will make brief daily visit to the study site to verify abstinence from smoking and participate in up to three cue-reactivity sessions. The cue-presentation task will involve visual, olfactory, and tactile cues. Participants will complete standardized mood questionnaires, and physiological responses will be measured.

Condition	Phase
Tobacco Smoking	Phase I

MedlinePlus related topics: Smoking

Drug Information available for: Nicotine polacrilex Nicotine tartrate

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective

Further study details as provided by National Institute on Drug Abuse (NIDA):

Biospecimen Retention: Samples Without DNA

Biospecimen Description:

saliva specimens

Estimated Enrollment:	420
Study Start Date:	July 2006
Estimated Study Completion Date:	July 2010

Groups/Cohorts
1 7-day smoking abstinence
2 14-day smoking abstinence
3 35-day smoking abstinence
3a 35-day smoking abstinence (within group time evaluation)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

healthy adult smokers

Criteria

Inclusion Criteria:

age 18 and over current tobacco smoker

Exclusion Criteria:

cognitive impairment medical or psychiatric conditions that would contraindicate participation

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00385060

Locations

United States, Illinois
University of Chicago	Recruiting
Chicago, Illinois, United States, 60637
Contact: Josh Shulruff 773-702-3560 dewitlab@yoda.bsd.uchicago.edu
Principal Investigator: Harriet de Wit, PhD
United States, Maryland
NIDA Intramural Research Program	Recruiting
Baltimore, Maryland, United States, 21224
Contact: Kenzie L Preston, PhD 443-740-2326 kpreston@intra.nida.nih.gov
Principal Investigator: Kenzie L Preston, PhD
Sub-Investigator: David H Epstein, PhD
Sub-Investigator: Stephen Heishman, PhD

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Harriet de Wit, PhD

University of Chicago

More Information

Responsible Party:	National Institute on Drug Abuse ( Kenzie L. Preston, Ph.D., Principal Investigator )
Study ID Numbers:	NIDAIRP411
Study First Received:	October 3, 2006
Last Updated:	October 3, 2008
ClinicalTrials.gov Identifier:	NCT00385060
Health Authority:	United States: Federal Government

Keywords provided by National Institute on Drug Abuse (NIDA):

tobacco
nicotine
abstinence
craving
cue-reactivity

Study placed in the following topic categories:

Nicotine polacrilex
Smoking
Nicotine

Additional relevant MeSH terms:

Habits

ClinicalTrials.gov processed this record on January 16, 2009